NCT06659549 - A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

March 30, 2027

Study Completion Date

May 30, 2027

Conditions

Geographic Atrophy of the Macula

Interventions

DRUG

GAL-101

Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

DRUG

Placebo

Patient will apply daily 2 eye drops of Placebo at 5 minutes interval

Trial Locations (12)

21740

RECRUITING

Cumberland Valley Retina Consultants, Hagerstown

33064

RECRUITING

Speciality Retina Center, Dr. Shailesh Gupta, Deerfield Beach

78240

RECRUITING

Retina Consultants of Texas - San Antonio, San Antonio

90211

RECRUITING

Retina-Vitreous Associates Medical Group, Beverly Hills

94598

RECRUITING

Bay Area Retina Associates, Walnut Creek

6423906

NOT_YET_RECRUITING

Tel Aviv Medical Center, Tel Aviv

9112001

NOT_YET_RECRUITING

Hadassah Medical Center, Jerusalem

0048

NOT_YET_RECRUITING

Ophthalmological Center After S.V. Malayan, Yerevan

0162

NOT_YET_RECRUITING

Akhali Mzera Limited, Tbilisi

0186

RECRUITING

Caucasus Medical Centre LLC, Tbilisi

Unknown

NOT_YET_RECRUITING

Chichua Medical Centre Mzera LLC, Tbilisi

X91 DH9W

RECRUITING

Institute of Eye Surgery (IOES Waterford), Waterford